1. Ratio of Fabry disease in patients with idiopathic left ventricular hypertrophy: A single-center study in Turkey
- Author
-
Nafiye Emel Çakar, Adem Atici, Mustafa Emir Tavşanlı, Sevgi Özcan, Caner Özgökçe, Ertugrul Okuyan, Mehmet Kucuk, Hasan Ali Barman, Irfan Sahin, Ahmet Öztürk, and Ayşegül Ezgi Kafalı
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Turkey ,Left ventricular hypertrophy ,Single Center ,White People ,Muscle hypertrophy ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,Humans ,echocardiography ,030212 general & internal medicine ,Prospective Studies ,cardiovascular diseases ,Prospective cohort study ,Original Investigation ,fabry disease ,business.industry ,Hypertrophic cardiomyopathy ,Enzyme replacement therapy ,Middle Aged ,medicine.disease ,hypertrophic cardiomyopathy ,Fabry disease ,Pedigree ,030104 developmental biology ,lcsh:RC666-701 ,alpha-Galactosidase ,Cohort ,Cardiology ,Female ,Hypertrophy, Left Ventricular ,Cardiology and Cardiovascular Medicine ,business - Abstract
Objective: Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism which arises due to deficient or absent activity of lysosomal α-galactosidase A (α-Gal A). This may be associated with increased left ventricular (LV) wall thickness and may mimic the morphological features of hypertrophic cardiomyopathy. The purpose of this study was to define the ratio of occurrence of FD to the manifestation of unexplained left ventricular hypertrophy (LVH). Methods: We studied a prospectively assembled a consecutive cohort of 190 patients with unexplained LVH on echocardiography. The criterion for LVH diagnosis was a maximum LV wall thickness of 13 mm or greater. All patients were tested for mutations in the GLA gene. Results: The majority of patients were male (n=119, 63%) and the mean patient age was 47.2+-15 years. In 190 patients diagnosed with LVH, we identified 2 patients (1.05%) with documented GLA mutations [c.427G>A (p.A143T)(p.Ala143Thr)] and [c.937G>T (p.D313Y)(p.Asp313Tyr)]. After the family screening, 3 additional patients with FD were identified in 2 families, including 5 individuals who are now receiving enzyme replacement therapy. Conclusion: We identified 2 index patients with FD and unexplained LVH. Cardiologists should, therefore, be aware of FD in cases of unexplained LVH. Family screening is crucial for the earlier identification of unaffected new patients who may benefit from enzyme replacement therapy.
- Published
- 2020